From the Guidelines
Yes, Fiasp (insulin aspart injection) can be used in insulin pumps, as it is an ultra-rapid-acting insulin that starts working faster than traditional rapid-acting insulins. When using Fiasp in a pump, follow the same basic principles as other pump insulins: change infusion sets and reservoirs every 2-3 days, monitor blood glucose levels frequently, and be prepared with backup insulin and supplies in case of pump failure. The faster onset of Fiasp may help provide better post-meal glucose control compared to standard rapid-acting insulins. However, this quicker action might require adjustments to your insulin-to-carbohydrate ratios and timing of bolus doses. Some patients may experience more frequent infusion site reactions with Fiasp compared to other insulins. Always consult with your healthcare provider before switching insulin types in your pump, as they can help determine appropriate dosing adjustments and monitor for any adverse effects, as noted in studies such as 1. Key considerations for using Fiasp in an insulin pump include:
- Patient selection: candidates for CSII must be strongly motivated to improve glucose control and willing to work with their healthcare provider, as indicated in 1.
- Insulin stability: rapid-acting insulin analogs, such as Fiasp, are appropriate for insulin infusion pumps, with confirmed stability in pumps, as seen in 1.
- Safety: pump therapy is as safe as multiple-injection therapy when recommended procedures are followed, but potential complications must be explained to users, as discussed in 1.
From the FDA Drug Label
If you use Insulin Aspart in an insulin pump, you should change your infusion set and insertion site according to the manufacturer’s user manual This Insulin Aspart product can be used with the continuous subcutaneous insulin infusion pumps labeled for use with NovoLog (insulin aspart) - refer to the insulin pump user manual to see if NovoLog can be used. Insulin Aspart should be given into an area of your body recommended in the instructions that come with your insulin pump
Fiasp (Insulin Aspart) can be used in an insulin pump, but it is essential to follow the manufacturer's user manual for specific instructions on usage and compatibility. The insulin pump should be labeled for use with NovoLog (insulin aspart). It is crucial to change the infusion set and insertion site according to the manufacturer's guidelines to minimize the risk of complications 2.
From the Research
Fiasp Use in Insulin Pumps
- Fiasp can be used in insulin pumps, as demonstrated by several studies 3, 4, 5, 6.
- A study published in 2018 found that Fiasp was safe and effective for use in insulin pumps, with no cases of infusion set plugging reported 3.
- A meta-analysis published in 2023 found that Fiasp use in insulin pumps was associated with improved post-prandial glycemic control and no increased risk of hypoglycemia 4.
- A single-center study published in 2023 found that Fiasp use in insulin pumps improved glycemic control in children and adolescents with type 1 diabetes mellitus 5.
- Another study published in 2019 compared the pharmacodynamics and pharmacokinetics of Fiasp, BioChaperone Lispro, and insulin aspart in patients with type 1 diabetes using insulin pumps, and found that Fiasp had similar early exposure and late exposure to BioChaperone Lispro 6.
Key Findings
- Fiasp use in insulin pumps is associated with improved post-prandial glycemic control 4, 5.
- Fiasp use in insulin pumps does not increase the risk of hypoglycemia 4, 7.
- Fiasp has similar pharmacodynamics and pharmacokinetics to BioChaperone Lispro in patients with type 1 diabetes using insulin pumps 6.
- Fiasp can be used safely and effectively in insulin pumps, with no reported cases of infusion set plugging 3.